Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

Historically, cancer-directed immune-based therapies have focused on eliciting a cytotoxic T
cell (CTL) response, primarily due to the fact that CTL can directly kill tumors. In addition …

The anti-cancer immune response against mutated peptides of potential immunological
relevance (neoantigens) is primarily attributed to MHC-I-restricted cytotoxic CD8+ T cell …

The identification of MHC class II restricted peptide epitopes is an important goal in
immunological research. A number of computational tools have been developed for this …

The technological advances occurred in the last few years have led to a great increase in
the number of tumor associated antigens (TAA) that are currently available for clinical …

The basic premise of the epitope-based approach to vaccine development is that, in certain
cases, the responses induced by the natural immunogen are not optimal, and can be …

Cellular immune responses that protect against tumors typically have been attributed to CD8
T cells. However, CD4 T cells also play a central role. It was shown recently that, in a patient …

Abstract The adenovirus type 5 (Ad5)-based vaccine developed by Merck failed to either
prevent HIV-1 infection or suppress viral load in subsequently infected subjects in the STEP …

The presence of a metaphase cytogenetic abnormality (CA) is the key negative predictor of
outcome in patients with multiple myeloma (MM). Gene expression profiling (GEP) of such …

MAGE-3 is the most commonly expressed cancer testis Ag and thus represents a prime
target for cancer vaccines, despite infrequent natural occurrence of MAGE-3-specific …